US FDA approves GSK's Hibsago for chronic hepatitis B

(AWP Alliance News) - The US FDA approved GSK's Hibsago (bepirovirsen) for chronic hepatitis B in eligible adults without cirrhosis, in combination with nucleos(t)ide analogue therapy. The six-month treatment achieved a 19% functional cure rate in phase III trials, versus 0% with placebo.

Disclaimer: This news brief was created using generative artificial intelligence. GSK plc published the original content used to generate this news brief via RNS, the regulatory disclosure system operated by the London Stock Exchange, on October 21, 2026, and is solely responsible for the information contained therein.